IpsenIPSEY +3.48%87 EV-to-FCF is 16.09 as of Jul. 07, 2026, which is 2% below its 10-year median of 16.46. GuruFocus rates IPSEY with a GF Score™ of 87/100 and a GF Value™ of $38.08 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 564 Drug Manufacturers companies, Ipsen ranks better than 60.11% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ipsen's Enterprise Value is $15,157 Mil.
Ipsen's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $942 Mil. Therefore, Ipsen's EV-to-FCF for today is 16.09.
The historical rank and industry rank for Ipsen's EV-to-FCF or its related term are showing as below:
IPSEY'
s EV-to-FCF Range Over the Past 10 Years
Min: -187.67 Med: 16.46 Max: 80.62
Current: 16.49
During the past 13 years, the highest EV-to-FCF of Ipsen was 80.62. The lowest was -187.67. And the median was 16.46.
IPSEY's EV-to-FCF is ranked better than 60.11% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.75
vs IPSEY: 16.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-07), Ipsen's stock price is $48.13.
Ipsen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $1.539. Therefore, Ipsen's PE Ratio (TTM) for today is 31.27.
Ipsen (OTCPK:IPSEY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ipsen's share price for today is $48.13.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ipsen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $1.539.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ipsen EV-to-FCF Related Terms
Ipsen EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Ipsen's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipsen EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipsen's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ipsen's EV-to-FCF falls into.
Ipsen's current Enterprise Value is $15,157 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ipsen's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $942 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipsen (IPSEY) has a EV-to-FCF of 16.09 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ipsen and its competitors. This is near median its historical median of 16.46. According to the industry distribution chart, Ipsen ranks #225 out of 564 companies in the Drug Manufacturers industry, placing it in the top 39.9%.
Is Ipsen's EV-to-FCF too high?
Ipsen's current EV-to-FCF of 16.09 is near median its 10-year median of 16.46. The Drug Manufacturers industry median EV-to-FCF is 20.75. Ipsen's value of 16.09 is 22.5% below this industry median. Based on the distribution chart, Ipsen ranks #225 out of 564 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ipsen has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipsen's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipsen ranks #225 out of 564 companies for EV-to-FCF. This puts Ipsen in the upper half of its industry. The industry median EV-to-FCF is 20.75. Ipsen's value of 16.09 is 22.5% below this benchmark. While the company's 10-year median is 16.46 vs. the industry median of 20.75, Ipsen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.75, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipsen's current EV-to-FCF of 16.09 is 22.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ipsen and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipsen's current EV-to-FCF is 16.09, which is near median its own 10-year median of 16.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Based on GuruFocus' analysis, Ipsen (IPSEY) is currently considered Modestly Overvalued. The stock's GF Value™ is $38.08, compared to a current price of $48.13 — trading 26.4% above its estimated fair value. The current EV-to-FCF is 16.09, which is near median its 10-year median of 16.46 and 22.5% below the Drug Manufacturers industry median of 20.75. Ipsen's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ipsen (IPSEY), the current EV-to-FCF is 16.09 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipsen (IPSEY) Overvalued in 2026?
Based on GuruFocus' analysis, Ipsen stock appears to be overvalued.
The current stock price of $48.13 is trading 26.4% above its estimated GF Value™ of $38.08.
GuruFocus considers Ipsen to be Modestly Overvalued.
Key valuation signals for IPSEY:
EV-to-FCF: 16.09 (near median its 10-year median of 16.46)
GF Value™: $38.08 vs. price of $48.13 (26.4% above fair value)
Industry Position: 22.5% below the Drug Manufacturers median (#225 of 564)
No single metric tells the full story. See the IPSEY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
87GF Score
Get the complete analysis for IPSEY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSEY has been successfully added to your 
